In terms of disease activity evaluated by physicians, we found that the serum levels of S100A12, S100B, S100A9, and HMGB1 in patients with very active vitiligo were significantly higher than those in patients in stable phase (S100A12, P=0.046; S100B, P=0.018; S100A9, P<0.001; HMGB1, P<0.001). This evidence concerns the gene S100A9 and vitiligo.